Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hematopoietic progenitor cells, cord blood (New York Blood Center)
- Development stage
- Approved
- Lead developer
- New York Blood Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Hematopoietic progenitor cells, cord blood is an **allogeneic cord blood-derived hematopoietic progenitor cell therapy** used for unrelated donor hematopoietic progenitor cell transplantation following an appropriate preparative regimen. The product consists of cryopreserved human umbilical cord blood cells containing hematopoietic stem and progenitor cells, including viable **CD34-positive** cells, that home to the **bone marrow**, engraft, proliferate, and differentiate to restore **hematopoietic and immunologic function** in patients with inherited or acquired disorders of the hematopoietic system or after myeloablative therapy. It is marketed through multiple licensed cord blood products, including **HemaCord**, **CordCyte**, **Allocord**, **Clevecord**, and **Ducord**, and represents a biologic **cell therapy/stem cell therapy** rather than a conventional single-molecule drug.
- Brand names
- HemaCordCordCyteAllocordClevecordDucord
- Other names
- hematopoietic progenitor cell, cord bloodhematopoietic progenitor cells, cord bloodHPCcord blood hematopoietic progenitor cellsumbilical cord blood hematopoietic progenitor cells
Beyond the preview
Go deeper on hematopoietic progenitor cells, cord blood (New York Blood Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hematopoietic progenitor cells, cord blood (New York Blood Center).